Retatrutide (Triple Agonist) Retatrutide (LY3437943) is Eli Lilly's investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously
It is engineered to interact with melanocortin receptors (MC1RMC5R), making it a valuable compound for laboratory studies focused on melanocortin signalling, receptor binding dynamics, and peptide-mediated neuroendocrine pathways
An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline
Researchers measure outcomes such as cell proliferation rate, migration assay results, collagen secretion (via ELISA or hydroxyproline assay), and gene expression changes via quantitative PCR or transcriptomics
At Potenziativa Medical Center in Como, Chelation Therapy with EDTA is performed under the supervision of Dr
To explore the underlying mechanism of SP@M in alleviating RA, the synovium and proliferated inflammation tissue around the joints in upper limbs in the saline group and SP@M group were isolated, respectively, for RNA sequencing analysis (Supplementary Fig
